Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established.
ARDX Ardelyx, Inc.
XNAS
2.95
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ARDX
$2.95
—
Key stats
$2.95
- 52-Week Range
- $2.90 – $8.40
- YTD
- -51.99%
- IV Rank (30D)
- 23.26
- Straddle Price
- $1.12
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.8B
- Open
- $2.99
- Day Range
- $2.90 – $2.99
- Volume
- 2,400,703
- Prev Close
- $2.99
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.95% |
| Beta vs SPY | 0.96 |
| Cost of Equity (CAPM) | 9.74% (VRP-adj) |
| WACC | 8.62% |
| Volatility Risk Premium | +134.7pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +1.9% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.02 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -33.8% |
| Book / Price | 22.2% |
| Gross Margin (TTM) | 94.5% |
| FCF Margin (TTM) | -3.4% |
| Debt / Equity | 1.54 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $3.37 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.12 |
| Bollinger Width / SMA20 | 391.9% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $1B |
Peers used for multiples: AMGN, BIIB, GILD, MRNA, NTRA, REGN, RPRX, VRTX
Blended Fair Value
$6.58
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 35.0× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 22.6× · 6 peers |
| Peer P/B | $7.28 | 18% | median 11.0× · 8 peers |
| Peer P/S | $17.14 | 18% | median 8.9× · 8 peers |
| Market Anchor (SMA50) | $3.37 | 64% | stability 69% (BB-width) |
| Options Expected (B-L 30d) | $3.01 | 0% | 6 strikes · skew +0.07 |
As of 2026-11-06 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.8B
- Employees
- 489
- List Date
- 2014-06-19
- CIK
- 0001437402
- Headquarters
- Fremont, CA
- Homepage
- https://www.ardelyx.com
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.95% | -29.98% | 9.33% | 44.30% | 4.69% | 25.04% | 9.72% |
| Feb | -7.33% | -8.18% | -4.32% | 0.32% | 1.32% | -15.92% | -5.68% |
| Mar | -3.64% | 46.98% | 64.04% | -21.84% | -3.35% | -7.42% | 12.46% |
| Apr | 6.56% | -23.09% | -5.51% | -13.63% | 14.93% | 3.60% | -2.86% |
| May | 5.93% | -21.70% | -28.17% | 3.78% | -32.91% | -12.21% | -14.21% |
| Jun | 6.01% | -4.90% | -3.14% | 7.08% | 1.82% | -10.99% | -0.69% |
| Jul | -78.11% | 17.51% | 19.39% | -26.68% | 8.72% | -3.32% | -10.41% |
| Aug | -16.07% | 42.41% | 10.94% | 12.36% | 46.88% | -24.10% | 12.07% |
| Sep | -8.97% | 21.43% | -15.35% | 22.38% | -13.91% | -9.04% | -0.58% |
| Oct | -6.92% | 11.94% | -2.71% | -14.31% | 13.06% | -10.36% | -1.55% |
| Nov | -5.79% | 9.55% | 14.47% | -6.90% | -2.03% | -2.48%* | 1.14% |
| Dec | -10.57% | 62.86% | 30.25% | -8.48% | 4.29% | -- | 15.67% |
| Total | -85.29% | 119.63% | 83.47% | -20.06% | 27.82% | -54.02% | 11.92% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.11
SMA 50: $3.35
SMA 200: $5.22
Current: $2.95
EMA 12: $3.08
EMA 26: $3.18
MACD: -0.0992 | Signal: 0.0120
BEARISH
ADX (14): 24.98
WEAK TREND
+DI: 22.37
−DI: 22.89
Momentum Oscillators
RSI (14): 39.16
NEUTRAL
Stoch %K: 30.37
Stoch %D: 33.67
Williams %R: -90.20
Volume & Volatility
BB Upper: $3.30
BB Lower: $2.92
NEUTRAL
OBV: -61,737,045
Vol SMA 20: 4,784,464
Vol ROC: -49.83%
ATR: $0.15
True Range: $0.09
HV 20: 60.5%
HV 30: 50.1%
HV 60: 43.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-05T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Technical indicators suggest a strong bearish momentum, with MACD and Stochastic signals aligning to confirm the downtrend.
- Recent news sentiment is mixed, but the negative headlines from Spherix Global Insights outweigh positive reports.
Primary Risks:
- The stock's beta of 0.8 indicates moderate volatility, which may amplify losses if the market corrects.
- Options activity suggests a bearish market expectation, with put-call volume and open interest ratios favoring puts.
Investment Thesis: ARX is likely to continue its downtrend due to mixed news sentiment and technical signals aligning against it. However, investors should consider hedging strategies or risk management approaches to mitigate potential losses.
Recent News Sentiment Impact: The negative headlines from Spherix Global Insights have dampened investor sentiment, contributing to the bearish momentum.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) BEARISH, Medium-term (1-3 months) BEARISH
Support/Resistance Levels:
- Lower Bollinger Band: $3.66
- Middle Line: $3.87
- Upper Band: $4.09
Momentum Signals:
- RSI (14): 32.35 (neutral)
- MACD: -0.26 / Signal: 0.04 / Histogram: -0.30 (bearish)
Volume Analysis:
- Volume SMA 20: 4362503.87
- On-Balance Volume (OBV): -44516206.47
News & Sentiment Analysis
Recent Headlines Summary: The news headlines are mixed, with negative reports from Spherix Global Insights and a positive article about the appointment of Rajani Dinavahi, MD, as Chief Medical Officer.
Sentiment Assessment: NEUTRAL (Aggregate sentiment)
Catalyst Identification: Earnings data is not available, but investors should monitor upcoming regulatory changes and product launches for potential catalysts.
Market Narrative: The recent news sentiment aligns with the bearish technical signals, suggesting a continued downtrend.
Risk & Volatility Assessment
Risk Assessment: ARX has moderate volatility (beta 0.8), which may amplify losses if the market corrects.
Volatility Regime: CURRENT VERSUS HISTORICAL VOLATILITY LEVELS The current volatility level is relatively high compared to historical averages, indicating a potentially more volatile market environment.
Options Market Signals:
- IV Rank: 59.5% (Medium)
- Current IV: 179.2%
- Expected Move: $0.57 (42 DTE), 7-DTE: $0.38
Downside Protection: The stock's lower Bollinger Band ($3.66) and support levels from moving averages provide some downside protection.
Market Context & Positioning
Sector Performance: ARX is underperforming the overall market, with a relative strength of -25% compared to the sector average.
Institutional Activity: Volume patterns suggest institutional interest in buying pressure is low.
Correlation Analysis: The stock's correlation with the market is relatively weak (R-squared 0.17), indicating a potential divergence from the broader market trend.
Relative Valuation: ARX is trading within its historical range, but the bearish momentum suggests it may be due for a correction.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $3.66
- Middle Line: $3.87
- Upper Band: $4.09
Breakout/Breakdown Levels:
- Resistance: $4.09 (upper band)
- Support: $3.66 (lower band)
Time-Sensitive Catalysts:
- Earnings data is not available, but monitor upcoming regulatory changes and product launches.
Risk Management: Consider stop-loss levels at the lower Bollinger Band ($3.66) or the middle line ($3.87), and adjust position sizing accordingly based on market conditions.
By analyzing the stock's technical indicators, news sentiment, and risk metrics, it is clear that ARX is likely to continue its downtrend due to mixed news sentiment and technical signals aligning against it. However, investors should consider hedging strategies or risk management approaches to mitigate potential losses.
Generated
News
All ARDX news →
Patient awareness push and IBSRELA sales growth both gained momentum this quarter.
Earnings History
18 of 25 under expected move
Avg Expected Move
28.43%
Avg Actual Move
12.25%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-08 | After-Close | 61.02% | 1.28% | 0.02x | Within |
| 2021-05-06 | After-Close | 16.92% | 1.81% | 0.11x | Within |
| 2021-07-19 | After-Close | 29.22% | 73.90% | 2.53x | Exceeded |
| 2021-11-12 | After-Close | 125.89% | 0.00% | 0.00x | Within |
| 2022-02-28 | After-Close | 38.96% | 5.45% | 0.14x | Within |
| 2022-05-05 | After-Close | 77.61% | 3.27% | 0.04x | Within |
| 2022-08-04 | After-Close | 30.49% | 4.02% | 0.13x | Within |
| 2022-11-03 | After-Close | 57.43% | 0.00% | 0.00x | Within |
| 2023-03-02 | After-Close | 11.42% | 32.18% | 2.82x | Exceeded |
| 2023-05-03 | After-Close | 12.82% | 0.43% | 0.03x | Within |
| 2023-08-02 | After-Close | 5.69% | 0.99% | 0.17x | Within |
| 2023-10-31 | After-Close | 15.19% | 0.25% | 0.02x | Within |
| 2024-01-08 | After-Close | 8.07% | 11.25% | 1.39x | Exceeded |
| 2024-02-22 | After-Close | 12.47% | 1.59% | 0.13x | Within |
| 2024-05-02 | After-Close | 14.43% | 28.42% | 1.97x | Exceeded |
| 2024-08-01 | After-Close | 28.64% | 10.00% | 0.35x | Within |
| 2024-10-31 | After-Close | 14.91% | 3.75% | 0.25x | Within |
| 2025-02-20 | Pre-Market | 13.36% | 10.06% | 0.75x | Within |
| 2025-05-01 | After-Close | 19.20% | 24.50% | 1.28x | Exceeded |
| 2025-08-04 | After-Close | 19.93% | 16.86% | 0.85x | Within |
| 2025-10-30 | After-Close | 25.95% | 20.96% | 0.81x | Within |
| 2026-01-08 | Pre-Market | 15.87% | 20.07% | 1.26x | Exceeded |
| 2026-04-30 | After-Close | 18.56% | 8.69% | 0.47x | Within |
| 2026-08-06 | After-Close | 16.94% | 17.86% | 1.05x | Exceeded |
| 2026-11-03 | After-Close | 19.80% | 8.58% | 0.43x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ARDX Options Activity & IV Rank
ARDX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 76.9%
7-DTE IV: 88.1%
Expected Move: $1.12
7-DTE Move: $0.53
Days to Exp: 42 (2026-12-18)
Options Flow
Call Volume: 150
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 157
Put OI: 0
P/C OI: —
Total OI: 157
ATM Options Pricing
ATM Call: $0.93
ATM Put: $0.20
Call %: 31.3%
Put %: 6.8%
Chain Summary
Chain Volume: 3,464
Chain OI: 256,243
Last Updated: 11/6/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 5th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
5%
vs own history
GEX tilt
-0.92
OI-weighted, today
Vanna tilt
-0.94
δ-sensitivity to IV
Charm tilt
+0.92
δ-decay vs time
Vanna tilt -0.94: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.92: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 89k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM 51.9% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)29.9MediumNov 6
IV Rank (30 DTE)23.3LowNov 6
Straddle Price (30 DTE)$1.12Nov 6
Beta Analysis
Risk Metrics
Beta: 0.9310
Alpha: -57.58%
Correlation: 0.2150
R-Squared: 4.6%
Stock Volatility: 58.7%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own ARDX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $70.9M | #467 of 3716 | -22.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $5.3M | #2052 of 6285 | -70.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $4.6M | #1516 of 3138 | -29.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $294K | #2387 of 4729 | +0.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ARDX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 246,900,850 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
11 filers$12.28M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | ORACLE INVESTMENT MANAGEMENT INC | $3.50M | 28.49% | 2025-12-31 |
| 2 | Susquehanna International Group, LLP Custodian | $1.56M | 12.69% | 2026-06-30 |
| 3 | Millennium Management LLC Custodian | $1.53M | 12.46% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.37M | 11.12% | 2026-06-30 |
| 5 | Stonepine Capital Management, LLC | $1.05M | 8.55% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $875.16K | 7.13% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $773.67K | 6.30% | 2026-06-30 |
| 8 | Caption Management, LLC | $765.00K | 6.23% | 2026-06-30 |
| 9 | Citadel Advisors LLC Custodian | $442.68K | 3.60% | 2026-06-30 |
| 10 | Raymond James Financial, Inc. Custodian | $250.00K | 2.04% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $171.72K | 1.40% | 2025-09-30 |
9 filers$7.11M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.03M | 28.61% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $1.55M | 21.74% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $1.05M | 14.76% | 2026-06-30 |
| 4 | Caption Management, LLC | $1.02M | 14.35% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $388.62K | 5.47% | 2026-06-30 |
| 6 | Millennium Management LLC Custodian | $365.67K | 5.14% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $297.83K | 4.19% | 2025-09-30 |
| 8 | IMC-Chicago, LLC Custodian | $204.51K | 2.88% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $202.98K | 2.86% | 2026-06-30 |
ARDX Insider Trading (Form 4)
Latest: 2026-08-25Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | Susan Hohenleitner | Chief Financial Officer | Sell (S) | −1,558 | $3.86 | -$6.0K | EDGAR |
| 2026-08-25 | Joseph James Reilly | See Remarks | Sell (S) | −3,982 | $3.86 | -$15.4K | EDGAR |
| 2026-08-25 | James Parker Brady | Chief Human Resources Officer | Sell (S) | −15,136 | $3.86 | -$58.4K | EDGAR |
| 2026-08-25 | John E Bishop | See Remarks | Sell (S) | −19,750 | $3.86 | -$76.2K | EDGAR |
| 2026-08-25 | Mike Kelliher | Chief Business Officer | Sell (S) | −7,758 | $3.86 | -$29.9K | EDGAR |
| 2026-08-25 | Michael Raab | President & CEO | Sell (S) | −58,574 | $3.86 | -$225.9K | EDGAR |
| 2026-08-25 | Laura A Williams | Chief Patient Officer | Sell (S) | −10,739 | $3.86 | -$41.4K | EDGAR |
| 2026-08-25 | Eric Duane Foster | Chief Commercial Officer | Sell (S) | −8,562 | $3.86 | -$33.0K | EDGAR |
| 2026-07-17 | Michael Raab | President & CEO | Mixed | −20,834 | $3.70 | -$190.3K | EDGAR |
| 2026-06-22 | Laura A Williams | Chief Patient Officer | Mixed | −50,898 | $4.62 | -$459.8K | EDGAR |
| 2026-06-18 | David M Mott | Director | Award (A) | +46,737 | — | EDGAR | |
| 2026-06-18 | William C Bertrand JR | Director | Award (A) | +38,800 | — | EDGAR | |
| 2026-06-18 | Muna Bhanji | Director | Award (A) | +26,455 | — | EDGAR | |
| 2026-06-18 | Onaiza Cadoret-Manier | Director | Award (A) | +26,455 | — | EDGAR | |
| 2026-06-18 | Richard J Rodgers | Director | Award (A) | +26,455 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ARDX Insider Holdings
19 insiders · @ $2.95
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David M Mott | Director | 6,831,841 | $20.15M | $65.06M | 31 | 2026-06-18 |
| 2 | Michael Raab | President & CEO | 1,644,156 | $4.85M | -$8.79M | 86 | 2026-08-25 |
| 3 | David P. Rosenbaum | Chief Development Officer | 448,378 | $1.32M | -$2.72M | 66 | 2024-11-22 |
| 4 | Richard J Rodgers | Director | 439,998 | $1.30M | $0 | 13 | 2026-06-18 |
| 5 | Eric Duane Foster | Chief Commercial Officer | 415,374 | $1.23M | -$277.4K | 9 | 2026-08-25 |
| 6 | Justin A Renz | Chief Financial Officer | 409,052 | $1.21M | -$1.80M | 30 | 2025-08-25 |
| 7 | Laura A Williams | Chief Patient Officer | 367,456 | $1.08M | -$3.34M | 29 | 2026-08-25 |
| 8 | Mike Kelliher | Chief Business Officer | 351,662 | $1.04M | -$253.6K | 9 | 2026-08-25 |
| 9 | William C Bertrand JR | Director | 329,507 | $972.0K | $100.0K | 14 | 2026-06-18 |
| 10 | John E Bishop | See Remarks | 317,095 | $935.4K | -$109.2K | 4 | 2026-08-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ARDX Board & Officers
As of SEC filings through Aug 25, 2026Directors 8
- David M Mott · since Jun 18, 2014
- Michael Raab · since Jun 18, 2014
- Richard J Rodgers · since Jun 18, 2014
- William C Bertrand JR · since Oct 26, 2015
- Robert B Bazemore · since Jun 2, 2016
- Onaiza Cadoret-Manier · since Mar 12, 2020
- Muna Bhanji · since Mar 11, 2021
- Merdad Parsey · since Apr 28, 2025
Officers 11
- Michael Raab · President & CEO · since Jun 18, 2014
- Joseph James Reilly · Senior Vice President and Chief Accounting Officer · listed since Feb 2026
- Susan Hohenleitner · Chief Financial Officer · since Nov 4, 2025
- Eric Duane Foster · Chief Commercial Officer · since Aug 8, 2024
- James Parker Brady · Chief Human Resources Officer · since Jun 18, 2025
- Edward R. Conner · Chief Medical Officer · since Aug 1, 2025
- John E Bishop · Chief Technical and Quality Officer · since Aug 1, 2025
- Laura A Williams · Chief Patient Officer · listed since Aug 2025
- Mike Kelliher · Chief Business Officer · listed since Aug 2025
- Rajani Dinavahi · Chief Medical Officer · since Apr 1, 2026
- Felecia Ettenberg · Chief Legal Officer · since Apr 20, 2026
Changes in the last 10 years (38)
| Apr 20, 2026 | Felecia Ettenberg became Chief Legal Officer |
| Apr 1, 2026 | Rajani Dinavahi became Chief Medical Officer |
| Feb 23, 2026 | Joseph James Reilly listed as Senior Vice President and Chief Accounting Officer (previously Senior Vice President of Finance) in SEC filings |
| Dec 17, 2025 | The company announced the departure of Elizabeth A Grammer as Chief Legal and Administrative Officer in an SEC filing |
| Nov 4, 2025 | Susan Hohenleitner became Chief Financial Officer |
| Aug 28, 2025 | Mike Kelliher listed as Chief Business Officer (previously Executive Vice President, Corporate Development and Strategy) in SEC filings |
| Aug 25, 2025 | Laura A Williams listed as Chief Patient Officer (previously Chief Medical Officer) in SEC filings |
| Aug 1, 2025 | John E Bishop became Chief Technical and Quality Officer |
| Aug 1, 2025 | Edward R. Conner became Chief Medical Officer |
| Jun 18, 2025 | James Parker Brady became Chief Human Resources Officer |
| Apr 28, 2025 | Merdad Parsey became a director |
| Nov 15, 2024 | Joseph James Reilly became Senior Vice President of Finance |
| Aug 8, 2024 | Eric Duane Foster became Chief Commercial Officer |
| Mar 25, 2024 | Mike Kelliher became Executive Vice President, Corporate Development and Strategy |
| Nov 13, 2023 | The company announced the departure of Geoffrey A. Block from the board in an SEC filing |
| Jun 15, 2022 | Laura A Williams became Chief Medical Officer |
| Mar 10, 2022 | Robert Ora Felsch became SVP Finance and Chief Accounting Officer |
| Dec 27, 2021 | Scott D Sandell reported in an SEC filing no longer being a 10% owner |
| Dec 27, 2021 | Forest Baskett reported in an SEC filing no longer being a 10% owner |
| Mar 11, 2021 | Muna Bhanji became a director |
| Dec 22, 2020 | Jeffrey W Jacobs listed as Chief Scientific Officer (previously SVP, Technical Operations) in SEC filings |
| Jun 12, 2020 | Patrick J Kerins reported in an SEC filing no longer being a 10% owner |
| Jun 12, 2020 | New Enterprise Associates 12, Limited Partnership reported in an SEC filing no longer being a 10% owner |
| Jun 12, 2020 | Nea 12 Gp, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 12, 2020 | NEA Partners 12, Limited Partnership reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2020 | David M Mott no longer listed as a 10% owner in SEC filings |
| Jun 9, 2020 | Robert Blanks became Chief Regulatory and Quality Affairs Officer |
| Jun 8, 2020 | Justin A Renz became Chief Financial Officer |
| May 18, 2020 | Susan Rodriguez became Chief Commercial Officer |
| Mar 12, 2020 | Onaiza Cadoret-Manier became a director |
| Mar 12, 2020 | Keith Santorelli became Principal Financial and Accounting Officer |
| Jan 13, 2020 | Elizabeth A Grammer listed as Chief Legal and Administrative Officer (previously EVP, General Counsel) in SEC filings |
| Mar 14, 2019 | Geoffrey A. Block became a director |
| Nov 15, 2018 | Elizabeth A Grammer listed as EVP, General Counsel (previously SVP, General Counsel) in SEC filings |
| Jun 1, 2018 | Mohamad Makhzoumi became a 10% owner |
| Mar 23, 2018 | Jan M Lundberg became a director |
| Apr 21, 2017 | David P. Rosenbaum listed as Chief Development Officer (previously SVP, Drug Development) in SEC filings |
| Dec 1, 2016 | Bryan Shaw became Chief Accounting Officer |
Not reported recently (24)
- Justin A Renz · Last reported as Chief Financial Officer in an SEC filing dated Aug 25, 2025
- David P. Rosenbaum · Last reported as Chief Development Officer in an SEC filing dated Nov 22, 2024
- Robert Blanks · Last reported as Chief Regulatory and Quality Affairs Officer in an SEC filing dated Nov 22, 2024
- Robert Ora Felsch · Last reported as SVP Finance and Chief Accounting Officer in an SEC filing dated Aug 22, 2024
- Susan Rodriguez · Last reported as Chief Commercial Officer in an SEC filing dated May 23, 2024
- Jan M Lundberg · Last reported as a director in an SEC filing dated Jun 16, 2023
- Jeffrey W Jacobs · Last reported as Chief Scientific Officer in an SEC filing dated Nov 24, 2021
- Gordon Ringold · Last reported as a director in an SEC filing dated Jun 11, 2020
- Keith Santorelli · Last reported as Principal Financial and Accounting Officer in an SEC filing dated Apr 7, 2020
- Peter J Barris · Last reported as a 10% owner in an SEC filing dated Dec 9, 2019
- Anthony A. Florence Jr. · Last reported as a 10% owner in an SEC filing dated Dec 9, 2019
- Peter W. Sonsini · Last reported as a 10% owner in an SEC filing dated Dec 9, 2019
- Joshua Makower · Last reported as a 10% owner in an SEC filing dated Dec 9, 2019
- Nea 15 Gp, LLC · Last reported as a 10% owner in an SEC filing dated Dec 9, 2019
- Mohamad Makhzoumi · Last reported as a 10% owner in an SEC filing dated Dec 9, 2019
- Mark Kaufmann · Last reported as Chief Financial Officer in an SEC filing dated Oct 8, 2019
- Annalisa Jenkins · Last reported as a director in an SEC filing dated Jun 17, 2019
- M James Barrett · Last reported as a 10% owner in an SEC filing dated May 30, 2018
- Ravi Viswanathan · Last reported as a 10% owner in an SEC filing dated May 30, 2018
- Jon Sakoda · Last reported as a 10% owner in an SEC filing dated May 30, 2018
- Jeremy S Caldwell · Last reported as EVP, Chief Scientific Officer in an SEC filing dated Jan 18, 2018
- Reginald Seeto · Last reported as Chief Operating Officer in an SEC filing dated Jan 18, 2018
- Paul Korner · Last reported as EVP, Chief Medical Officer in an SEC filing dated Jan 23, 2017
- Bryan Shaw · Last reported as Chief Accounting Officer in an SEC filing dated Dec 16, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ARDX Proposed Insider Sales (Form 144)
Latest: 2026-08-21
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
8 filings
· $524K notice value
· 8 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
RAAB MICHAEL (1, $179K) · Bishop John E (1, $103K) · Brady James Parker (1, $79K) · Foster Eric Duane (1, $48K) · Kelliher Mike (1, $42K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-21 | Hohenleitner Susan | Officer | 2,650 | $10.7K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Brady James Parker | Officer | 19,700 | $79.4K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Reilly Joseph James | Officer | 4,700 | $18.9K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Foster Eric Duane | Officer | 11,900 | $48.0K | 2026-08-21 | Morgan Stanley Smith Barney LLC,… | — | EDGAR |
| 2026-08-21 | Kelliher Mike | Officer | 10,500 | $42.3K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Williams Laura A | Officer | 10,500 | $42.3K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | RAAB MICHAEL | Officer | 44,500 | $179.3K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Bishop John E | Officer | 25,500 | $102.8K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-18 | LAURA WILLIAMS | Officer | 81,898 | $478.3K | 2026-06-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-17 144/A | RAAB MICHAEL | Officer, Director | 41,666 | $236.7K | 2026-06-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
48 ETFs hold ARDX
25 shown · $121.68M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $25.3M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.23% | $25.1M | $10.9B | 2026-11-04 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $20.7M | $75.4B | 2026-11-04 |
| 4 | PBE Invesco Biotechnology & Genome ETF | Invesco | 2.23% | $10.1M | — | 2026-11-04 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $9.6M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.05% | $7.5M | $13.4B | 2026-11-04 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $7.0M | — | 2026-05-31 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $4.9M | — | 2026-09-30 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.5M | — | 2026-09-30 |
| 10 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.2M | $92.8B | 2026-11-04 |
| 11 | BBP Virtus Biotech Etf | Nport | 1.20% | $1.2M | — | 2026-07-31 |
| 12 | TSCV Thrivent Small Cap Value ETF | Nport | 0.58% | $1.1M | — | 2026-06-30 |
| 13 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.16% | $1.0M | — | 2026-11-05 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.05% | $907,969 | — | 2026-09-30 |
| 15 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $871,928 | — | 2026-05-31 |
| 16 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $584,189 | — | 2026-07-31 |
| 17 | ISMD Inspire Small/Mid Cap ETF | Nport | 0.15% | $511,139 | — | 2026-08-31 |
| 18 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $390,437 | $4.1B | 2026-11-04 |
| 19 | RSSL Global X Russell 2000 ETF | Global X | 0.03% | $347,854 | — | 2026-11-05 |
| 20 | BBSC JPMorgan BetaBuilders U.S. Small Cap Equity ETF | JPMorgan | 0.03% | $205,299 | $708.1M | 2026-11-05 |
| 21 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $191,004 | $19.6B | 2026-11-04 |
| 22 | ISCG iShares Morningstar Small-Cap Growth ETF | iShares (BlackRock) | 0.01% | $139,190 | $926.7M | 2026-11-04 |
| 23 | FSML Franklin Small Cap Enhanced ETF | Franklin | 0.09% | $127,550 | $145.5M | 2026-11-05 |
| 24 | TILT FlexShares Morningstar US Market Factor Tilt Index Fund | Nport | 0.00% | $85,308 | — | 2026-07-31 |
| 25 | ISCV iShares Morningstar Small-Cap Value ETF | iShares (BlackRock) | 0.01% | $69,656 | $687.1M | 2026-11-04 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.22
TTM Revenue
$468.22M
TTM Net Income
$-55.47M
TTM Op. Cash Flow
$-15.51M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $127.66M | $-737.00K | $0.00 | $2.17M |
| Q2 '26 | 2026-06-30 | $120.88M | $-16.72M | $-0.07 | $-6.40M |
| Q1 '26 | 2026-03-31 | $94.47M | $-37.60M | $-0.15 | $-32.24M |
| Q4 '25 | 2025-12-31 | $125.22M | $-407.00K | $-0.01 | $20.95M |
| Q3 '25 | 2025-09-30 | $110.33M | $-969.00K | $0.00 | $365.00K |
| Q2 '25 | 2025-06-30 | $97.66M | $-19.08M | $-0.08 | $-25.34M |
| Q1 '25 | 2025-03-31 | $74.11M | $-41.14M | $-0.17 | $-38.46M |
| Q4 '24 | 2024-12-31 | $116.13M | $4.64M | $0.02 | $9.81M |
| Q3 '24 | 2024-09-30 | $98.24M | $-809.00K | — | $501.00K |
| Q2 '24 | 2024-06-30 | $73.22M | $-16.45M | $-0.07 | $-19.40M |
| Q1 '24 | 2024-03-31 | $46.02M | $-26.52M | $-0.11 | $-35.72M |
| Q4 '23 | 2023-12-31 | $34.36M | $-28.80M | $-0.13 | $-8.72M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.84
P/S
1.60
EV/EBITDA
—
EV/Sales
1.94
ROE
-37.4%
ROA
-9.7%
Div Yield
0.00%
FCF Yield
-2.40%
Debt/Equity
1.69
Current Ratio
—
Market Cap
$721.66M
as of 2026-11-06
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
30.24M
SI % of Float
12.44%
Days to Cover
6.48
Short Vol Ratio
41.0%
Free Float
243.16M
Float %
97.6%
Short interest 2026-10-15 • Short volume 2026-11-05 • Float 2026-08-07